Is B-type natriuretic peptide-guided heart failure management cost-effective?

International Journal of Cardiology

Volumn 96, Issue 2, 2004, Pages 177-181

  Morimoto, Takeshi ^a   Hayashino, Yasuaki ^a   Shimbo, Takuro ^a   Izumi, Tohru ^b   Fukui, Tsuguya ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B type natriuretic peptide; Chronic heart failure; Cost effectiveness analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MORTALITY; OUTPATIENT; POPULATION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BIOLOGICAL MARKERS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 3242779406     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.05.036     Document Type: Article

References (20)

1. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am. J. Cardiol. 83:(2A):1999;1A-38A
2. Cleland J.G., Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am. J. Cardiol. 83:(5B):1999;112D-119D
3. Richards A.M., Lainchbury J.G., Nicholls M.G., Troughton R.W., Yandle T.G. BNP in hormone-guided treatment of heart failure. Trends Endocrinol. Metab. 13:(4):2002;151-155
4. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:(9210):2000;1126-1130
5. Daly C., Fox K., Henein M. Natriuretic peptides in the diagnosis of heart disease - first amongst equals? Int. J. Cardiol. 84:(2-3):2002;107-113
6. Kalra P.R., Struthers A.D. More evidence for bedside BNP in heart failure assessment. Int. J. Cardiol. 86:(2-3):2002;149-152
7. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham study. J. Am. Coll. Cardiol. 22:(4 Suppl. A):1993;6A-13A
8. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York
9. Thaulow E., Jorgensen B., Doyle J.J., et al. A pharmacoeconomic evaluation of results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES) in Norway and Canada. Int. J. Cardiol. 84:(1):2002;23-30. (discussion 30-2)
10. Paul S.D., Kuntz K.M., Eagle K.A., Weinstein M.C. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch. Intern. Med. 154:(10):1994;1143-1149
11. Delea T.E., Vera-Llonch M., Richner R.E., Fowler M.B., Oster G. Cost effectiveness of carvedilol for heart failure. Am. J. Cardiol. 83:(6):1999;890-896
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. New Engl. J. Med. 325:(5):1991;293-302
13. Beck J.R., Kassirer J.P., Pauker S.G. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am. J. Med. 73:(6):1982;883-888
14. Morimoto T., Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J. Epidemiol. 12:(2):2002;160-178
15. Havranek E.P., McGovern K.M., Weinberger J., Brocato A., Lowes B.D., Abraham W.T. Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. J. Card. Fail. 5:(2):1999;85-91
16. News Flash (January 1, 2002). Department of Laboratory, University of Washington. (http://depts.washington.edu/labweb/test/nf/jan02.pdf).
17. WSR 02-13-099. Department of Social and Health Services, Washington State Register. (http://slc.leg.wa.gov/wsr/2002/13/02-13-099.htm).
18. Hlatky M.A. Economic endpoints in clinical trials. Epidemiol. Rev. 24:(1):2002;80-84
19. Weintraub W.S., Cole J., Tooley J.F. Cost and cost-effectiveness studies in heart failure research. Am. Heart J. 143:(4):2002;565-576
20. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing not Properly (BNP) Multinational Study. Circulation. 106:(4):2002;416-422